NYMXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (7 7月 2023 @ 05:00):

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally...

Stats
本日の出来高	881 574
平均出来高	134 777
時価総額	18.24M
EPS	$0.0100 ( 2023-08-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.161 (16.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2022-05-02	Robinson James George	Buy	1 151 515	Warrant
2021-04-22	Robinson James George	Buy	200	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 546 252 \| Sell: 0

ボリューム相関

長: -0.08 (neutral)

短: -0.02 (neutral)

Signal:(67.127) Neutral

Nymox Pharmaceutical Corp 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Nymox Pharmaceutical Corp 相関 - 通貨/商品

-0.25
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

-0.04
( neutral )

0.38
( neutral )

Nymox Pharmaceutical Corp 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.0735

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.0735

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.150

FY	2020
収益:	$5 000.00
総利益:	$1 000.00 (20.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.